Novo Nordisk Ceases Production Of One Long-Acting Insulin In US Amid Manufacturing Constraints, Competition
Novo Nordisk A/S (NYSE: NVO) has reportedly discontinued its long-acting insulin Levemir in the U.S., attributing the decision to manufacturing constraints, reduced patient access, and the availability of alternative options.